We could not find any results for:
Make sure your spelling is correct or try broadening your search.
GT Biopharma Inc is an immuno-oncology company operating in the United States. It is engaged in discovering, developing and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cance... GT Biopharma Inc is an immuno-oncology company operating in the United States. It is engaged in discovering, developing and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its key drug candidates are OXS-2175, targeting the treatment of triple-negative breast cancer; OXS-4235, targets the treatment of multiple myeloma and associated osteolytic lesions; and OXS-1550, targets cancer cells expressing the CD19 receptor and CD22 receptor. Its TriKE and TetraKE platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.41 | -11.051212938 | 3.71 | 3.71 | 2.9539 | 8232 | 3.16545407 | CS |
4 | -1.29 | -28.1045751634 | 4.59 | 4.68 | 2.9539 | 7087 | 3.70432345 | CS |
12 | -1.61 | -32.7902240326 | 4.91 | 5.21 | 2.9539 | 13304 | 4.27646609 | CS |
26 | -5.1 | -60.7142857143 | 8.4 | 9.9 | 2.9539 | 82353 | 6.81871912 | CS |
52 | -7.5 | -69.4444444444 | 10.8 | 16.11 | 2.9539 | 225491 | 8.59593751 | CS |
156 | -395.7 | -99.1729323308 | 399 | 591.993 | 2.9539 | 212250 | 136.02237067 | CS |
260 | -161.7 | -98 | 165 | 591.993 | 2.9539 | 243732 | 154.3156766 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions